Trial Profile
An Extension Study of Linifanib in Subjects With Advanced or Metastatic Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Nov 2017
Price :
$35
*
At a glance
- Drugs Linifanib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 02 Aug 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
- 01 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 May 2012 Planned End Date changed from 1 Feb 2013 to 1 Jun 2012 as reported by ClinicalTrials.gov.